FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Editta Baldini

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Stefania Gori; claudio graiff; Gianluigi Lunardi; Annamaria Molino; Antonio Muggiano; Giuliano Pandoli; Carmine Pinto; Fabio Puglisi; Pierosandro Tagliaferri; Silverio Tomao; Marco Venturini; Oscar Alabiso; Editta Baldini; Enrico Barbato; Giordano Domenico Beretta; Stefano Bravi; Orazio Caffo; Luciano Canobbio; Francesco Carrozza; Saverio Cinieri; Giorgio Cruciani; Massimo Di Maio; Angelo Dinota; Vittorio Gebbia; Lucio Giustini
Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Stefania Gori; claudio graiff; Annamaria Molino; Salvatore Siena; Emiliana Tarenzi; Oscar Alabiso; Giuseppe Altavilla; Editta Baldini; Matteo Clavarezza; Davide Dondi; Jennifer Foglietta; Vittorio Fusco; Teresa Gamucci; Monica Giordano; Marco Venturini
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
Stefania Gori; claudio graiff; Annamaria Molino; Antonio Muggiano; Giuliano Pandoli; Carmine Pinto; Fabio Puglisi; Pierosandro Tagliaferri; Silverio Tomao; Marco Venturini; Oscar Alabiso; Editta Baldini; Enrico Barbato; Giordano Domenico Beretta; Stefano Bravi; Orazio Caffo; Luciano Canobbio; Francesco Carrozza; Saverio Cinieri; Giorgio Cruciani; Massimo Di Maio; Angelo Dinota; Vittorio Gebbia; Lucio Giustini
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Editta Baldini (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Stefania Gori; claudio graiff; Gianluigi Lunardi; Annamaria Molino; Antonio Muggiano; Giuliano Pandoli; Carmine Pinto; Fabio Puglisi; Pierosandro Tagliaferri; Silverio Tomao; Marco Venturini; Oscar Alabiso; Editta Baldini; Enrico Barbato; Giordano Domenico Beretta; Stefano Bravi; Orazio Caffo; Luciano Canobbio; Francesco Carrozza; Saverio Cinieri; Giorgio Cruciani; Massimo Di Maio; Angelo Dinota; Vittorio Gebbia; Lucio Giustini
Impact of use of oral anticancer drugs on activity of Italian oncology practices: results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Tumori 2013;99(1):35-8.
2012: Stefania Gori; claudio graiff; Annamaria Molino; Salvatore Siena; Emiliana Tarenzi; Oscar Alabiso; Giuseppe Altavilla; Editta Baldini; Matteo Clavarezza; Davide Dondi; Jennifer Foglietta; Vittorio Fusco; Teresa Gamucci; Monica Giordano; Marco Venturini
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
BMC cancer 2012;12():158.
2011: Stefania Gori; claudio graiff; Annamaria Molino; Antonio Muggiano; Giuliano Pandoli; Carmine Pinto; Fabio Puglisi; Pierosandro Tagliaferri; Silverio Tomao; Marco Venturini; Oscar Alabiso; Editta Baldini; Enrico Barbato; Giordano Domenico Beretta; Stefano Bravi; Orazio Caffo; Luciano Canobbio; Francesco Carrozza; Saverio Cinieri; Giorgio Cruciani; Massimo Di Maio; Angelo Dinota; Vittorio Gebbia; Lucio Giustini
Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Tumori 2011;97(4):442-8.
2011: Dino Amadori; Rosella Silvestrini; Mario De Lena; Francesco Boccardo; Andrea Rocca; Emanuela Scarpi; Francesco Schittulli; Mario Brandi; Roberta Maltoni; Patrizia Serra; Riccardo Ponzone; Nicoletta Biglia; Lorenzo Gianni; Amelia Tienghi; Maria Rosaria Valerio; Paola Bonginelli; Laura Amaducci; Marina Faedi; Editta Baldini; angelo paradiso
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Breast cancer research and treatment 2011;125(3):775-84.
2010: Stefania Gori; Massimo Di Maio; Carmine Pinto; Oscar Alabiso; Editta Baldini; Giordano Domenico Beretta; Orazio Caffo; Cinzia Caroti; Lucio Crinò; Michelino De Laurentiis; Angelo Dinota; Francesco Di Vito; Vittorio Gebbia; Lucio Giustini; claudio graiff; Michele Guida; Giorgio Lelli; Marco Lombardo; Antonio Muggiano; Fabio Puglisi; Sante Romito; Luigi Salvagno; Pierosandro Tagliaferri; Edmondo Terzoli; Marco Venturini
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
Tumori 2010;96(6):1010-5.
2009: Laura Boldrini; Greta Alì; Silvia Gisfredi; Silvia Ursino; Editta Baldini; Franca Melfi; Marco Lucchi; Camilla E Comin; Cristina Maddau; Carmelo Tibaldi; Tiziano Camacci; Adele Servadio; Alfredo Mussi; Gabriella Fontanini
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Oncology reports 2009;22(4):683-91.
2009: Alessandra Capodanno; Andrea Camerini; Cinzia Orlandini; Editta Baldini; Maria Letizia Resta; Generoso Bevilacqua; Paola Collecchi
Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.
Human pathology 2009;40(10):1408-17.
2008: Lucia Del Mastro; B Dozin; Enrico Aitini; Tiziana Catzeddu; Editta Baldini; Antonio Contu; Antonio Durando; S Danese; Giovanna Cavazzini; Giuseppe Canavese; Paolo Bruzzi; Paolo Pronzato; Marco Venturini
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(2):299-307.
2008: Editta Baldini; Tiziana Prochilo; Laura Boldrini; Franca Melfi; Gabriella Fontanini
Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.
Molecular medicine reports 2008;1(1):41-3.
2008: Chiara Schivazappa; Patrizia Berto; Editta Baldini; Sandro Barni; Giuliana Dauria; Enrico Cortesi
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Recenti progressi in medicina 2008;99(1):27-31.
2007: Laura Boldrini; Silvia Gisfredi; Silvia Ursino; Tiziano Camacci; Editta Baldini; Franca Melfi; Gabriella Fontanini
Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(12):1086-90.
2007: Cesare Gridelli; Carmine Ferrara; Ciro Guerriero; Salvatore Palazzo; Giuseppe Grasso; Ida Pavese; Francesco Satta; Emilio Bajetta; Diego Cortinovis; Fausto Barbieri; Vittorio Gebbia; Francesco Grossi; Silvia Novello; Editta Baldini; Giampietro Gasparini; Walter Latino; Emilia Durante; Lucio Giustini; Cristina Negrini
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):475-80.
2007: Marco Lucchi; Franca Melfi; Editta Baldini; Gabriella Fontanini; Giuseppe Boni; Andrea Viti; Alfredo Mussi
Sentinel lymph node mapping: detection of micrometastases by polymerase chain reaction in non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(5 Suppl):S37.
2007: Chiara Schivazappa; Editta Baldini; Enrico Cortesi; Giuliana Dauria; Fausto Roila; Patrizia Berto
[Cost analysis of tumor-induced osteolysis treated with intravenous zoledronic acid and pamidronate: a time-motion study].
Recenti progressi in medicina 2007;98(1):12-5.
2006: Editta Baldini; Andrea Camerini; Alessandro Sgambato; Tiziana Prochilo; Alessandra Capodanno; Francesco Pasqualetti; Cinzia Orlandini; Letizia Resta; Generoso Bevilacqua; Paola Collecchi
Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients.
Anticancer research 2006;26(6B):4415-21.
2006: Carmelo Tibaldi; Tiziana Prochilo; Francesa Russo; MC Pennucci; A Del Freo; Federico Innocenti; A Fabbri; Alfredo Falcone; Pier Franco Conte; Editta Baldini
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
British journal of cancer 2006;94(9):1263-6.
2005: Marco Venturini; Lucia Del Mastro; Enrico Aitini; Editta Baldini; Cinzia Caroti; Antonio Contu; Franco Testore; Fulvio Brema; Paolo Pronzato; Giovanna Cavazzini; Mario Roberto Sertoli; Giuseppe Canavese; Riccardo Rosso; Paolo Bruzzi
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Journal of the National Cancer Institute 2005;97(23):1724-33.
2005: Andrea Ardizzoni; ADOLFO FAVARETTO; Luca Boni; Editta Baldini; Federico Castiglioni; Paola Antonelli; Franca Pari; Carmelo Tibaldi; Alfonso M Altieri; Santi Barbera; Giancarlo Cacciani; Mario Raimondi; Lucia Tixi; Micaela Stefani; Silvio Monfardini; Antonio Antilli; Riccardo Rosso; Adriano Paccagnella
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(3):569-75.
2004: Editta Baldini; Giovanni Gardin; Giuseppe Evagelista; Tiziana Prochilo; Paola Collecchi; Rita Lionetto
Long-term results of combined-modality therapy for inflammatory breast carcinoma.
Clinical breast cancer 2004;5(5):358-63.
2004: Pier Franco Conte; Valentina Guarneri; Paolo Bruzzi; Tiziana Prochilo; Barbara Salvadori; Angelo Bolognesi; Daniela Aldrighetti; Marco Venturini; Riccardo Rosso; Serafina Mammoliti; Flavio Carnino; Piergiorgio Giannessi; Massimo Costantini; Alfredo Moyano; Editta Baldini
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Cancer 2004;101(4):704-12.
2004: Editta Baldini; Tiziana Prochilo; Barbara Salvadori; A Bolognesi; Daniela Aldrighetti; Marco Venturini; Riccardo Rosso; Flavio Carnino; Luigi Gallo; Piergiorgio Giannessi; Pier Franco Conte; Cinzia Orlandini; Paolo Bruzzi
Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel in metastatic breast cancer patients: focus on cardiac safety.
British journal of cancer 2004;91(1):45-9.
2004: Editta Baldini; Tiziana Prochilo
[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: what kind of evidence?].
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2004;3(4):S79-80.
2003: Editta Baldini
No consensus on the optimal palliative radiotherapy regimen for people with inoperable non-small-cell lung cancer.
Cancer treatment reviews 2003;29(5):445-7.
2003: Editta Baldini; Giovanni Gardin; Piergiorgio Giannessi; Giuseppe Evangelista; Manuela Roncella; Tiziana Prochilo; Paola Collecchi; Riccardo Rosso; Rita Lionetto; Paolo Bruzzi; F Mosca; Pier Franco Conte
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):227-32.
2002: Editta Baldini; Andrea Ardizzoni; Tiziana Prochilo; Maria A Cafferata; Luca Boni; Carmelo Tibaldi
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
Cancer chemotherapy and pharmacology 2002;49 Suppl 1():S25-8.
2002: Romano Danesi; Federico Innocenti; Stefano Fogli; Alessandra Gennari; Editta Baldini; Antonello Di Paolo; Barbara Salvadori; Guido Bocci; Pier Franco Conte; Mario Del Tacca
Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
British journal of clinical pharmacology 2002;53(5):508-18.
2001: Editta Baldini; Andrea Ardizzoni; Tiziana Prochilo; M A Cafferata; Luca Boni; Carmelo Tibaldi; Carlo Emanuele Neumaier; Pier Franco Conte; Riccardo Rosso
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
British journal of cancer 2001;85(10):1452-5.
2001: Pier Franco Conte; Alessandra Gennari; Sara Donati; Barbara Salvadori; Editta Baldini; Carmelo Bengala; I Pazzagli; Cinzia Orlandini; Romano Danesi; Stefano Fogli; Mario Del Tacca
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Breast cancer research and treatment 2001;68(2):171-9.
2001: PierFranco Conte; Alessandra Gennari; Valentina Guarneri; Elisabetta Landucci; Sara Donati; Barbara Salvadori; Carmelo Bengala; Cinzia Orlandini; Editta Baldini
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials.
Oncology (Williston Park, N.Y.) 2001;15(5 Suppl 7):21-3.
2000: Editta Baldini; Giovanni Silvano; Carmelo Tibaldi; Silvana Campoccia; Luca Cionini; PierFranco Conte
Sequential chemoradiation therapy with vinorelbine, ifosfamide, and cisplatin in stage IIIB non-small cell lung cancer: a phase II study.
Seminars in oncology 2000;27(1 Suppl 1):28-32.
1999: Paola Collecchi; A Passoni; M Rocchetta; E Gnesi; Editta Baldini; Generoso Bevilacqua
Cyclin-D1 expression in node-positive (N+) and node-negative (N-) infiltrating human mammary carcinomas.
International journal of cancer. Journal international du cancer 1999;84(2):139-44.
1998: Paola Collecchi; Editta Baldini; Piergiorgio Giannessi; Antonio Giuseppe Naccarato; A Passoni; Giovanni Gardin; Manuela Roncella; Giuseppe Evangelista; Generoso Bevilacqua; Pier Franco Conte
Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, bcl-2 expression and the relationship between tumour regression and biological markers.
European journal of cancer (Oxford, England : 1990) 1998;34(11):1701-4.
1998: Editta Baldini; Carmelo Tibaldi; Andrea Ardizzoni; F Salvati; Antonio Antilli; Luigi Portalone; Santi Barbera; F Romano; Filippo De Marinis; Maria Rita Migliorino; MA Noseda; U Borghini; M Crippa; G Ferrara; M Raimondi; M Fioretti; M Bandera; MC Pennucci; G Galeasso; Giancarlo Cacciani; G Lepidini; G Sunseri; C Lanfranco; Massimo Rinaldi; Riccardo Rosso
Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP).
British journal of cancer 1998;77(12):2367-70.
1998: Editta Baldini; Carmelo Tibaldi; F Chiavacci; M Di Lieto; L Fioretto; A Giallom-bardo; R Taviani; P Ghezzi; A Bolognini; PierFranco Conte
Epirubicin/vinorelbine as first line therapy in metastatic breast cancer.
Breast cancer research and treatment 1998;49(2):129-34.
1997: Editta Baldini; Giovanni Gardin; Piergiorgio Giannessi; Fulvio Brema; A Camorriano; Flavio Carnino; C Naso; G Pastorino; Paolo Pronzato; Riccardo Rosso; Alessandra Rubagotti; G Torretta; Pier Franco Conte
A randomized trial of chemotherapy with or without estrogenic recruitment in locally advanced breast cancer. North-West Oncology Group (GONO) Study, Italy.
Tumori 1997;83(5):829-33.
1997: Pier Franco Conte; Editta Baldini; Alessandra Gennari; Andrea Michelotti; Barbara Salvadori; Carmelo Tibaldi; Romano Danesi; Federico Innocenti; A Gentile; R Dell'Anna; O Biadi; M Mariani; Mario Del Tacca
Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2510-7.
1997: Editta Baldini; Carmelo Tibaldi; Monica Lencioni; Piergiorgio Giannessi; Giuseppe Evangelista; Manuela Roncella; C Spinelli; C Meucci; M da Prato; PierFranco Conte
Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients.
American journal of clinical oncology 1997;20(2):169-72.
1996: Pier Franco Conte; Editta Baldini; Andrea Michelotti; Barbara Salvadori; Alessandra Gennari; M Da Prato; Carmelo Tibaldi; Piergiorgio Giannessi; A Gentile
Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
Seminars in oncology 1996;23(6 Suppl 15):39-42.
1996: Editta Baldini; Carmelo Tibaldi; Elisabetta Pfanner; S Ricci; Alfredo Falcone; Anna Ceribelli; R Sarcina; Giuseppe Comella; C G Stampino; Pier Franco Conte
Phase II study of oral doxifluridine in elderly patients with advanced non-small-cell lung cancer.
American journal of clinical oncology 1996;19(6):592-4.
1996: Andrea Michelotti; Alessandra Gennari; Barbara Salvadori; A Tognoni; Carmelo Tibaldi; Editta Baldini; Pier Franco Conte
Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(8):857-60.
1996: Andrea Michelotti; Alessandra Gennari; Barbara Salvadori; Piergiorgio Giannessi; Editta Baldini; Carmelo Tibaldi; M Da Prato; Pier Franco Conte
Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
Seminars in oncology 1996;23(5 Suppl 11):38-40.
1996: Pier Franco Conte; Andrea Michelotti; Editta Baldini; Barbara Salvadori; Alessandra Gennari; M Da Prato; Carmelo Tibaldi; E Salzano; A Gentile
A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer.
Seminars in oncology 1996;23(5 Suppl 11):28-31.
1996: Carmelo Tibaldi; Editta Baldini; S Ricci; Pier Franco Conte
A pilot study with cisplatin, ifosfamide and weekly administration of vinorelbine as an outpatient combination chemotherapy for advanced non small cell lung cancer.
Anticancer research 1996;16(5B):3213-5.
1996: Editta Baldini; Carmelo Tibaldi; Antonio Chella; Carlo Alberto Angeletti; Giovanni Silvano; A Andrei; R Algeri; Pier Franco Conte
Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(7):747-9.
1996: Pier Franco Conte; Editta Baldini; Giovanni Gardin; Paolo Pronzato; D Amadori; Flavio Carnino; C Monzeglio; P Gentilini; P Gallotti; R DeMicheli; Marco Venturini; Alessandra Rubagotti; R Rosso
Chemotherapy with or without estrogenic recruitment in metastatic breast cancer. A randomized trial of the Gruppo Oncologico Nord Ovest (GONO).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(5):487-90.
1996: Paola Collecchi; Piergiorgio Giannessi; Editta Baldini; Antonio Giuseppe Naccarato; A Passoni; Generoso Bevilacqua; Pier Franco Conte
Effects of primary chemotherapy on biological parameters of locally advanced breast cancer.
Annals of the New York Academy of Sciences 1996;784():419-26.
1996: Pier Franco Conte; Andrea Michelotti; Editta Baldini; Carmelo Tibaldi; M DaPrato; Barbara Salvadori; Piergiorgio Giannessi; A Gentile; Ombretta Biadi; Mario Mariani
Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
Seminars in oncology 1996;23(1 Suppl 1):28-32.
1995: Andrea Ardizzoni; G F Addamo; Editta Baldini; U Borghini; Luigi Portalone; Filippo De Marinis; R Lionetto; P F Conte; Paolo Bruzzi; MC Pennucci
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.
British journal of cancer 1995;71(1):115-9.
1994: Editta Baldini; Piergiorgio Giannessi; Giovanni Gardin; Angela Alama; Francesco Minuto; Antonina Barreca; Pier Franco Conte
In vivo cytokinetic effects of recombinant human growth hormone (rhGH) in patients with advanced breast carcinoma.
Journal of biological regulators and homeostatic agents 1994;8(4):113-6.
1994: Editta Baldini; Carmelo Tibaldi; Antonio Chella; Carlo Alberto Angeletti; A Romanini; A Andrei; R Algeri; Giovanni Silvano; Pier Franco Conte
Combination chemotherapy with vinorelbine, ifosfamide, and cisplatin: a phase II study in stage IIIB-IV non-small cell lung cancer.
Seminars in oncology 1994;21(3 Suppl 4):12-5.
1994: Andrea Ardizzoni; marco bonavia; M Viale; Editta Baldini; C Mereu; A Verna; S Ferrini; A Cinquegrana; S Molinari; G L Mariani
Biologic and clinical effects of continuous infusion interleukin-2 in patients with non-small cell lung cancer.
Cancer 1994;73(5):1353-60.
1993: Editta Baldini; Giovanni Gardin; C Naso; Paolo Pronzato; R Rosso; Alessandra Rubagotti; C Monzeglio; Fulvio Brema; G Pastorino; D Amadori
Stimulation of human breast cancer in vivo. Experimental findings and clinical results.
Annals of the New York Academy of Sciences 1993;698():418-22.
1992: E Campora; Paolo Pronzato; Domenico Amoroso; Gianfilippo Bertelli; Marco Venturini; Editta Baldini; Isa Maura Brunetti; Mario Roberto Sertoli; PierFranco Conte; R Rosso
Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF.
Anticancer research 1992;12(5):1555-8.
1991: Andrea Ardizzoni; R Rosso; F Salvati; Giorgio V Scagliotti; E Soresi; G Ferrara; C Pennucci; Editta Baldini; A R Cruciani; Antonio Antilli
Combination chemotherapy and interferon alpha 2b in the treatment of advanced non-small-cell lung cancer. The Italian Lung Cancer Task Force (FONICAP).
American journal of clinical oncology 1991;14(2):120-3.
1991: Andrea Ardizzoni; V Fusco; C Pennucci; Editta Baldini; M Orsatti; Vito Vitale; marco bonavia; F Baracco; C Mereu; R Rosso
Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
Anticancer research 1991;11(2):681-4.
1990: E Campora; Editta Baldini; Alessandra Rubagotti; Silvana Chiara; Paolo Bruzzi; Mario Roberto Sertoli; R Rosso
Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy.
Journal of chemotherapy (Florence, Italy) 1990;2(5):336-9.
1990: Andrea Ardizzoni; Mario Roberto Sertoli; A Corcione; MC Pennucci; Editta Baldini; E Intra; M Ferrarini; R Rosso; P Mazzanti; Vito Pistoia
Accelerated chemotherapy with or without GM-CSF for small cell lung cancer: a non-randomised pilot study.
European journal of cancer (Oxford, England : 1990) 1990;26(9):937-41.